Tag: file

LOS ANGELES, Aug. 9, 2025 /PRNewswire/ -- Thumzup Media Corporation (Nasdaq: TZUP) ("Thumzup" or the "Company"), a digital asset accumulator and advertising industry disruptor, today...

NEW ORLEANS, Aug. 8, 2025 /PRNewswire/ -- ClaimsFiler, a FREE shareholder information service, reminds investors that they have until August 25, 2025 to file...

LOS ANGELES, Aug. 8, 2025 /PRNewswire/ -- Thumzup Media Corporation (Nasdaq: TZUP) ("Thumzup" or the "Company"), a digital asset accumulator and advertising industry disruptor, today...

Nurse Practitioners, Physician Assistants, and Certified Nurse Midwives at Cape Cod Healthcare move to join the MNA for an equal voice in clinical decisions CAPE...

The dividend will cover the period through August 21, 2025

The dividend will cover the period through August 21, 2025

MALVERN, Pa., Aug. 08, 2025 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced that it has entered into a securities purchase agreement with Janus Henderson Investors, a global asset management firm, to purchase 20,000,000 shares of common stock and warrants to purchase up to an aggregate of 20,000,000 shares of common stock at a purchase price of $1.00 per share (closing price on August 7, 2025) and accompanying warrant in a registered direct offering. The warrants have an exercise price of $1.50 per share, are exercisable immediately upon issuance, and will expire two years following the date of issuance. The warrants are callable by the Company when the VWAP of the Company’s common stock exceeds $2.50 per share for at least five of a trailing 30 trading day period. 

JUNO BEACH, Fla., Aug. 8, 2025 /PRNewswire/ -- Florida Power & Light Company and key stakeholder groups have reached an agreement in principle on...

Faraday Future Announces the Upcoming Special Meeting to Enable Rapid Execution of the Second Chapter of the Bridge Strategy and Adhere to Prudent Issuance

SAN DIEGO, Aug. 08, 2025 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics Inc. (NYSE American: CLDI) (“Calidi”), a clinical-stage biotechnology company pioneering the development of targeted therapies with the potential to deliver genetic medicines to distal sites of disease, today reported its second quarter 2025 operating and financial results and reviewed recent business highlights.

Company to host an investor conference call and webcast at 4:30 pm ET

Company to host an investor conference call and webcast at 4:30 pm ET

Surrozen Reports Second Quarter 2025 Financial Results and Provides Business Update